New Zealand markets open in 5 hours 26 minutes

Ocular Therapeutix, Inc. (OCUL)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
5.40-0.08 (-1.46%)
As of 10:34AM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 501.80M
Enterprise value 381.25M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)13.46
Price/book (mrq)5.75
Enterprise value/revenue 9.89
Enterprise value/EBITDA -4.82

Trading information

Stock price history

Beta (5Y monthly) 1.72
52-week change 3-70.59%
S&P500 52-week change 314.85%
52-week high 321.48
52-week low 35.18
50-day moving average 36.53
200-day moving average 310.72

Share statistics

Avg vol (3-month) 3818.84k
Avg vol (10-day) 3628.84k
Shares outstanding 576.61M
Implied shares outstanding 6N/A
Float 869.77M
% held by insiders 10.41%
% held by institutions 159.53%
Shares short (13 Jan 2022) 43.18M
Short ratio (13 Jan 2022) 44.72
Short % of float (13 Jan 2022) 44.63%
Short % of shares outstanding (13 Jan 2022) 44.15%
Shares short (prior month 14 Dec 2021) 43.36M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sep 2021


Profit margin -229.01%
Operating margin (ttm)-192.75%

Management effectiveness

Return on assets (ttm)-29.41%
Return on equity (ttm)-212.26%

Income statement

Revenue (ttm)38.56M
Revenue per share (ttm)0.51
Quarterly revenue growth (yoy)106.80%
Gross profit (ttm)-13.37M
EBITDA -71.81M
Net income avi to common (ttm)-88.31M
Diluted EPS (ttm)-1.97
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)179.28M
Total cash per share (mrq)2.34
Total debt (mrq)58.73M
Total debt/equity (mrq)67.24
Current ratio (mrq)8.11
Book value per share (mrq)1.14

Cash flow statement

Operating cash flow (ttm)-56.64M
Levered free cash flow (ttm)-40.9M